Novo Resources Corp is starting a 2,700-metre reverse circulation drilling program at its Tibooburra Gold Project in New South Wales. The drilling will focus on extending high-grade gold mineralisation at the Clone prospect, where previous results showed up to 13.7 g/t gold, and test a new target at Pioneer South, which has not been drilled before despite strong surface gold findings. This program aims to help Novo earn a 70% interest in the project and form a joint venture, with further exploration planned for 2027 including a major soil-sampling campaign to understand the broader 22-kilometre mineralised system and identify the source of the gold.
Novo Nordisk announced that its ZEUS phase 3 trial testing ziltivekimab, an IL-6 pathway inhibitor, in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation did not reduce major adverse cardiovascul...
Novo Nordisk's shares fell 9.3%, wiping out over $30 billion in market value after its experimental heart drug ziltivekimab failed to meet trial goals for reducing major cardiovascular events. Analysts criticized the failure as a missed chance to div...
Shares of Novo Nordisk fell sharply after the company announced that its late-stage trial for the heart drug ziltivekimab did not significantly reduce major cardiovascular events like heart attack, stroke, or cardiovascular death compared to a placeb...
Novo Resources is set to start a 2,700-metre drilling program at its Tibooburra Gold Project in New South Wales in late September 2026, pending approvals. Pantoro Gold reported solid gold production and cost efficiency at its Norseman mine, with grow...
Novo Resources is advancing exploration at the Tibooburra Gold Project in NSW through a joint venture with Manhattan Gold Corporation. A ~2,700 meter reverse circulation (RC) drilling program is planned to begin in late Q3 2026, focusing on the Clone...
